COMP <GO>
ALKS vs AXSM // EV/EBITDA & P/E VALUATION
Alkermes plc (NASDAQ) VS. Axsome Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ALKS 9
— AXSM 2
■ METRIC PARITY
LAST: $44.89 (-0.99%) • MKT CAP: $7.61B
valuation
25.1x
LAST: $136.01 (-5.83%) • MKT CAP: $7.57B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALKS VS. AXSM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALKS | AXSM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.00% | -21.90% | +35.90 | ALKS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 25.1x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 6.31% | -1.25% | +7.56 | ALKS | /fcf-yield <GO> |
| Operating Margin | 17.20% | -26.10% | +43.30 | ALKS | /operating-margins <GO> |
| Net Profit Margin | 16.40% | -28.70% | +45.10 | ALKS | /net-margins <GO> |
| Revenue Growth (YoY) | -5.20% | 65.50% | -70.70 | AXSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.03 | 5.34 | +2.69 | ALKS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | ALKS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.0 | 25.9 | +35.10 | ALKS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.15 | -0.10 | AXSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.3x | 35.0x | -5.70 | ALKS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.61B | $7.57B | $41.0M | ALKS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALKS REV | AXSM REV | ALKS GROSS % | AXSM GROSS % | ALKS FCF | AXSM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.48B | $638.5M | 86.7% | — | $480.3M | -$93.9M |
| FY 2024 | $1.56B | $385.7M | 84.2% | — | $405.6M | -$128.7M |
| FY 2023 | $1.66B | $270.6M | — | — | $326.5M | -$157.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALKS // BETA 1.05
AXSM // BETA 1.15